How have EVOK shares performed in 2023?

Evoke Pharma's stock was trading at $2.68 at the beginning of the year. Since then, EVOK shares have decreased by 55.2% and is now trading at $1.2001. View the best growth stocks for 2023 here .

Are investors shorting Evoke Pharma?

Evoke Pharma saw a increase in short interest in November. As of November 15th, there was short interest totaling 22,500 shares, an increase of 54.1% from the October 31st total of 14,600 shares. Based on an average trading volume of 12,200 shares, the short-interest ratio is currently 1.8 days. Currently, 0.7% of the company's stock are short sold. View Evoke Pharma's Short Interest .

When is Evoke Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 19th 2024. View our EVOK earnings forecast .

How were Evoke Pharma's earnings last quarter?

Evoke Pharma, Inc. (NASDAQ:EVOK) released its earnings results on Thursday, November, 9th. The specialty pharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter. The specialty pharmaceutical company had revenue of $1.56 million for the quarter. Evoke Pharma had a negative net margin of 176.93% and a negative trailing twelve-month return on equity of 517.99%.

When did Evoke Pharma's stock split?

Evoke Pharma's stock reverse split before market open on Monday, May 23rd 2022. The 1-12 reverse split was announced on Monday, May 23rd 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 23rd 2022. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

What other stocks do shareholders of Evoke Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Evoke Pharma investors own include Bank of Hawaii (BOH) , InterDigital (IDCC) , STAG Industrial (STAG) , Advanced Micro Devices (AMD) , Novavax (NVAX) , Sorrento Therapeutics (SRNE) , Inovio Pharmaceuticals (INO) , Pfizer (PFE) , Gilead Sciences (GILD) and Bed Bath & Beyond (BBBY) .

Who are Evoke Pharma's major shareholders?

Evoke Pharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David A Gonyer and Matthew J D'onofrio. View institutional ownership trends .

How do I buy shares of Evoke Pharma?

Shares of EVOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Evoke Pharma Stock Price, News & Analysis (NASDAQ:EVOK)

$1.21

-0.02 (-1.33%)

(As of 11:50 AM ET)

Compare

Today's Range: $1.20
▼
$1.24
50-Day Range: $1.08
▼
$1.39
52-Week Range: $0.92
▼
$5.96

Volume: 8,914 shs
Average Volume: 23,473 shs
Market Capitalization: $4.05 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Evoke Pharma Stock (NASDAQ:EVOK)

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

EVOK Stock Price History

30 days | 90 days | 365 days | Advanced Chart

EVOK Stock News Headlines

December 6, 2023 | morningstar.com

Evoke Pharma Inc EVOK

December 5, 2023 | americanbankingnews.com

Evoke Pharma (NASDAQ:EVOK) Receives New Coverage from Analysts at StockNews.com

December 8, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

December 3, 2023 | americanbankingnews.com

Evoke Pharma (NASDAQ:EVOK) vs. Immunic (NASDAQ:IMUX) Head to Head Contrast

November 30, 2023 | finance.yahoo.com

Revolutionizing gastroparesis treatment: Evoke Pharma's CEO talks game-changing nasal spray

November 27, 2023 | finanznachrichten.de

Evoke Pharma, Inc.: Evoke Pharma Announces FDA Orange Book Listing of New GIMOTI Patent

November 14, 2023 | marketwatch.com

Evoke Pharma Shares Rise on New Gimoti U.S. Patent

November 14, 2023 | finance.yahoo.com

United States Patent and Trademark Office (USPTO) Grants Another Formulation Patent Covering GIMOTI

December 8, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 10, 2023 | msn.com

Evoke Pharma files to sell common stock and warrants

November 9, 2023 | benzinga.com

Evoke Pharma: Q3 Earnings Insights

November 9, 2023 | msn.com

Evoke Pharma GAAP EPS of -$0.51, revenue of $1.56M

November 9, 2023 | finance.yahoo.com

Evoke Pharma Reports Third Quarter 2023 Financial Results

November 5, 2023 | msn.com

Why Are There So Many Pharma Stories Right Now?

October 31, 2023 | finance.yahoo.com

Evoke Pharma & EVERSANA Unveil Cost Savings Real-World Data Demonstrating Meaningfully Reduced Healthcare Costs for Patients Using GIMOTI Over Oral Metoclopramide Presented at the American College of Gastroenterology 2023

October 30, 2023 | markets.businessinsider.com

Evoke Announces Appointment of Group President Cris Morton

October 25, 2023 | msn.com

REVIEW: ‘Pain Hustlers’ Needs A Higher Dosage Of Fresh Ideas

October 23, 2023 | markets.businessinsider.com

7 Under-the-Radar Growth Stocks Ready to Make a Splash

October 18, 2023 | finance.yahoo.com

Evoke Pharma’s Abstract Entitled “Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs in Treating Diabetic Gastroparesis Patients” to Be Presented at The American College of Gastroenterology (ACG) 2023 Annual Meeting

September 14, 2023 | finanznachrichten.de

Evoke Pharma, Inc.: Evoke Pharma Receives Notice of Allowance from USPTO for GIMOTI

September 14, 2023 | finance.yahoo.com

Evoke Pharma Receives Notice of Allowance from USPTO for GIMOTI®

August 15, 2023 | finance.yahoo.com

Evoke launches audience intelligence offering to unlock full commercial potential of life sciences brands

August 10, 2023 | msn.com

Evoke Pharma GAAP EPS of -$0.56 beats by $0.17, revenue of $1.13M beats by $0.03M

August 10, 2023 | finanznachrichten.de

Evoke Pharma, Inc.: Evoke Pharma Reports Second Quarter 2023 Financial Results

August 10, 2023 | finance.yahoo.com

Evoke Pharma Reports Second Quarter 2023 Financial Results

August 8, 2023 | msn.com

Mayo's Aidan O'Shea and fiancée Kristin celebrate engagement in exotic location

August 7, 2023 | finance.yahoo.com

Evoke Pharma and EVERSANA Announce Abstract Acceptance at 2023 American Neurogastroenterology and Motility Society (ANMS) Meeting

See More Headlines

Receive EVOK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evoke Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/09/2023
Today: 12/08/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/19/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:EVOK
CUSIP: N/A
CIK: 1403708
Web: www.evokepharma.com
Phone: (858) 345-1494
Fax: N/A
Employees: 4
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($2.27)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-8,220,000.00
Net Margins: -176.93%
Pretax Margin: -176.93%
Return on Equity: -517.99%
Return on Assets: -78.59%

Debt

Debt-to-Equity Ratio: 9.29
Current Ratio: 3.50
Quick Ratio: 3.27

Sales & Book Value

Annual Sales: $4.30 million
Price / Sales: 0.95
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.22 per share
Price / Book: 1.01

Miscellaneous

Outstanding Shares: 3,343,000
Free Float: 2,949,000
Market Cap: $4.10 million
Optionable: Not Optionable
Beta: 0.32

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. David A. Gonyer R.Ph. (Age 59)
Co-Founder, CEO & Director
Comp: $806.53k
Mr. Matthew J. D'Onofrio MBA (Age 53)
Co-Founder, President, COO, Secretary & Treasurer
Comp: $557.11k
Dr. Marilyn R. Carlson (Age 75)
Chief Medical Officer
Comp: $518.14k
Mr. Christopher Quesenberry
Chief Commercial Officer - Gimoti (TM)

Key Competitors

View All Competitors

EVOK Stock Analysis - Frequently Asked Questions

How have EVOK shares performed in 2023?: Evoke Pharma's stock was trading at $2.68 at the beginning of the year. Since then, EVOK shares have decreased by 55.2% and is now trading at $1.2001.
View the best growth stocks for 2023 here.
Are investors shorting Evoke Pharma?: Evoke Pharma saw a increase in short interest in November. As of November 15th, there was short interest totaling 22,500 shares, an increase of 54.1% from the October 31st total of 14,600 shares. Based on an average trading volume of 12,200 shares, the short-interest ratio is currently 1.8 days. Currently, 0.7% of the company's stock are short sold.
View Evoke Pharma's Short Interest.
When is Evoke Pharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 19th 2024.
View our EVOK earnings forecast.
How were Evoke Pharma's earnings last quarter?: Evoke Pharma, Inc. (NASDAQ:EVOK) released its earnings results on Thursday, November, 9th. The specialty pharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter. The specialty pharmaceutical company had revenue of $1.56 million for the quarter. Evoke Pharma had a negative net margin of 176.93% and a negative trailing twelve-month return on equity of 517.99%.

When did Evoke Pharma's stock split?: Evoke Pharma's stock reverse split before market open on Monday, May 23rd 2022. The 1-12 reverse split was announced on Monday, May 23rd 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 23rd 2022. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.
What other stocks do shareholders of Evoke Pharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Evoke Pharma investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), Advanced Micro Devices (AMD), Novavax (NVAX), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Pfizer (PFE), Gilead Sciences (GILD) and Bed Bath & Beyond (BBBY).
Who are Evoke Pharma's major shareholders?: Evoke Pharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David A Gonyer and Matthew J D'onofrio.
View institutional ownership trends.
How do I buy shares of Evoke Pharma?: Shares of EVOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:EVOK) was last updated on 12/8/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial